Neuphoria Therapeutics (NEUP) Receivables - Net (2020 - 2025)
Neuphoria Therapeutics (NEUP) has disclosed Receivables - Net for 5 consecutive years, with $1.1 million as the latest value for Q4 2025.
- On a quarterly basis, Receivables - Net rose 3021.14% to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 million, a 3021.14% increase, with the full-year FY2025 number at $11948.0, changed N/A from a year prior.
- Receivables - Net was $1.1 million for Q4 2025 at Neuphoria Therapeutics, up from $1758.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $1.1 million in Q4 2025 to a low of $1758.0 in Q3 2025.
- A 4-year average of $169457.9 and a median of $30076.5 in 2024 define the central range for Receivables - Net.
- Biggest YoY gain for Receivables - Net was 3021.14% in 2025; the steepest drop was 98.48% in 2025.
- Neuphoria Therapeutics' Receivables - Net stood at $46099.0 in 2022, then plummeted by 78.66% to $9836.9 in 2023, then soared by 261.51% to $35561.0 in 2024, then soared by 3021.14% to $1.1 million in 2025.
- Per Business Quant, the three most recent readings for NEUP's Receivables - Net are $1.1 million (Q4 2025), $1758.0 (Q3 2025), and $11948.0 (Q2 2025).